<VariationArchive VariationID="1184270" VariationName="NM_000051.4(ATM):c.9007_9034del (p.Asn3003fs)" VariationType="Deletion" Accession="VCV001184270" Version="8" RecordType="classified" NumberOfSubmissions="4" NumberOfSubmitters="4" DateLastUpdated="2024-07-29" DateCreated="2021-07-24" MostRecentSubmission="2024-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1174033" VariationID="1184270">
      <GeneList>
        <Gene Symbol="ATM" FullName="ATM serine/threonine kinase" GeneID="472" HGNC_ID="HGNC:795" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>11q22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="108223067" stop="108369102" display_start="108223067" display_stop="108369102" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="108093558" stop="108239825" display_start="108093558" display_stop="108239825" Strand="+" />
          </Location>
          <OMIM>607585</OMIM>
          <Haploinsufficiency last_evaluated="2020-04-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=ATM">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-04-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=ATM">No evidence available</Triplosensitivity>
        </Gene>
        <Gene Symbol="C11orf65" FullName="chromosome 11 open reading frame 65" GeneID="160140" HGNC_ID="HGNC:28519" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>11q22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="108308519" stop="108469881" display_start="108308519" display_stop="108469881" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="108253726" stop="108338257" display_start="108253726" display_stop="108338257" Strand="-" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_000051.4(ATM):c.9007_9034del (p.Asn3003fs)</Name>
      <CanonicalSPDI>NC_000011.10:108365343:AACAAAGTAGCTGAACGTGTCTTAATGA:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>11q22.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="108365344" stop="108365371" display_start="108365344" display_stop="108365371" variantLength="28" positionVCF="108365343" referenceAlleleVCF="CAACAAAGTAGCTGAACGTGTCTTAATGA" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="108236071" stop="108236098" display_start="108236071" display_stop="108236098" variantLength="28" positionVCF="108236070" referenceAlleleVCF="CAACAAAGTAGCTGAACGTGTCTTAATGA" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>N3003fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.10" sequenceAccession="NC_000011" sequenceVersion="10" change="g.108365344_108365371del" Assembly="GRCh38">
            <Expression>NC_000011.10:g.108365344_108365371del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.9" sequenceAccession="NC_000011" sequenceVersion="9" change="g.108236071_108236098del" Assembly="GRCh37">
            <Expression>NC_000011.9:g.108236071_108236098del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009830.1" sequenceAccession="NG_009830" sequenceVersion="1" change="g.147513_147540del">
            <Expression>NG_009830.1:g.147513_147540del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_054724.1" sequenceAccession="NG_054724" sequenceVersion="1" change="g.109462_109489del">
            <Expression>NG_054724.1:g.109462_109489del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000051.3" sequenceAccession="NM_000051" sequenceVersion="3" change="c.9007_9034del28">
            <Expression>NM_000051.3:c.9007_9034del28</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000042.3" sequenceAccession="NP_000042" sequenceVersion="3" change="p.Asn3003Aspfs">
            <Expression>NP_000042.3:p.Asn3003Aspfs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000051.4" sequenceAccession="NM_000051" sequenceVersion="4" change="c.9007_9034del" MANESelect="true">
            <Expression>NM_000051.4:c.9007_9034del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000042.3" sequenceAccession="NP_000042" sequenceVersion="3" change="p.Asn3003fs">
            <Expression>NP_000042.3:p.Asn3003fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001351834.2" sequenceAccession="NM_001351834" sequenceVersion="2" change="c.9007_9034del">
            <Expression>NM_001351834.2:c.9007_9034del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001338763.1" sequenceAccession="NP_001338763" sequenceVersion="1" change="p.Asn3003fs">
            <Expression>NP_001338763.1:p.Asn3003fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001330368.2" sequenceAccession="NM_001330368" sequenceVersion="2" change="c.640+20549_640+20576del">
            <Expression>NM_001330368.2:c.640+20549_640+20576del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001351110.2" sequenceAccession="NM_001351110" sequenceVersion="2" change="c.694+20549_694+20576del">
            <Expression>NM_001351110.2:c.694+20549_694+20576del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_135" sequenceAccession="LRG_135">
            <Expression>LRG_135:g.147513_147540del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_135t1" sequenceAccession="LRG_135t1">
            <Expression>LRG_135t1:c.9007_9034del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2137906600" DB="dbSNP" />
      </XRefList>
      <FunctionalConsequence Value="Unknown function" />
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000051.4(ATM):c.9007_9034del (p.Asn3003fs) AND Familial cancer of breast" Accession="RCV001542261" Version="12">
        <ClassifiedConditionList TraitSetID="774">
          <ClassifiedCondition DB="MedGen" ID="C0346153">Familial cancer of breast</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-02-06" SubmissionCount="2">Pathogenic/Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000051.4(ATM):c.9007_9034del (p.Asn3003fs) AND Hereditary cancer-predisposing syndrome" Accession="RCV001692466" Version="11">
        <ClassifiedConditionList TraitSetID="13598">
          <ClassifiedCondition DB="MedGen" ID="C0027672">Hereditary cancer-predisposing syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-06-17" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000051.4(ATM):c.9007_9034del (p.Asn3003fs) AND Ataxia-telangiectasia syndrome" Accession="RCV003106231" Version="10">
        <ClassifiedConditionList TraitSetID="770">
          <ClassifiedCondition DB="MedGen" ID="C0004135">Ataxia-telangiectasia syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-10-13" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-02-06" NumberOfSubmissions="4" NumberOfSubmitters="4" DateCreated="2021-07-24" MostRecentSubmission="2024-05-01">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11298136</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17600866</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27664052</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30192042</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31050087</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33280026</ID>
        </Citation>
        <DescriptionHistory Dated="2021-09-23">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="13598" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18746" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Tumor predisposition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer predisposition</ElementValue>
                <XRef ID="Hereditary+Cancer/3345" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary neoplastic syndrome</ElementValue>
                <XRef ID="MONDO:0015356" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neoplastic Syndromes, Hereditary</ElementValue>
                <XRef ID="D009386" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Cancer Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
                <XRef ID="699346009" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="19921" />
                <XRef ID="19921" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="general" Abbrev="IARC, 2008">
                <ID Source="pmc">3075918</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <XRef ID="140162" DB="Orphanet" />
              <XRef ID="C0027672" DB="MedGen" />
              <XRef ID="D009386" DB="MeSH" />
              <XRef ID="MONDO:0015356" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="770" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4635" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Ataxia-telangiectasia syndrome</ElementValue>
                <XRef ID="Ataxia+Telangiectasia/637" DB="Genetic Alliance" />
                <XRef ID="68504005" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Louis-Bar syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cerebello-oculocutaneous telangiectasia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Immunodeficiency with ataxia telangiectasia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ataxia-telangiectasia, complementation group E</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ataxia-telangiectasia, complementation group D</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">AT, COMPLEMENTATION GROUP C</ElementValue>
                <XRef ID="208900" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ATAXIA-TELANGIECTASIA, COMPLEMENTATION GROUP A</ElementValue>
                <XRef Type="Allelic variant" ID="607585.0001" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ATAXIA-TELANGIECTASIA, FRESNO VARIANT</ElementValue>
                <XRef Type="Allelic variant" ID="607585.0014" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ataxia-telangiectasia</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">AT1</ElementValue>
                <XRef Type="MIM" ID="208900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">AT</ElementValue>
                <XRef Type="MIM" ID="208900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ATE</ElementValue>
                <XRef ID="208900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">A-T</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ATM</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ATC</ElementValue>
                <XRef ID="208900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ATA</ElementValue>
                <XRef ID="208900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ATD</ElementValue>
                <XRef ID="208900" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5862" />
                <XRef ID="5862" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Classic ataxia-telangiectasia (A-T) is characterized by progressive cerebellar ataxia beginning between ages one and four years, oculomotor apraxia, choreoathetosis, telangiectasias of the conjunctivae, immunodeficiency, frequent infections, and an increased risk for malignancy, particularly leukemia and lymphoma. Individuals with A-T are unusually sensitive to ionizing radiation. Non-classic forms of A-T have included adult-onset A-T and A-T with early-onset dystonia.</Attribute>
                <XRef ID="NBK26468" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301790</ID>
                <ID Source="BookShelf">NBK26468</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301317</ID>
                <ID Source="BookShelf">NBK1138</ID>
              </Citation>
              <Citation Type="general" Abbrev="EFNS, 2010">
                <ID Source="PubMed">20050888</ID>
              </Citation>
              <Citation Type="general" Abbrev="EFNS/ENS, 2014">
                <ID Source="PubMed">24418350</ID>
              </Citation>
              <XRef ID="100" DB="Orphanet" />
              <XRef ID="C0004135" DB="MedGen" />
              <XRef ID="MONDO:0008840" DB="MONDO" />
              <XRef Type="MIM" ID="208900" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="774" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="536" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Familial cancer of breast</ElementValue>
                <XRef ID="Familial+cancer+of+breast/8375" DB="Genetic Alliance" />
                <XRef ID="254843006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast cancer, familial</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561700" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17142" />
                <XRef ID="17142" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="St. Gallen, 2021">
                <ID Source="PubMed">34242744</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2024">
                <URL>https://www.nice.org.uk/guidance/ng101</URL>
                <CitationText>UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024</CitationText>
              </Citation>
              <XRef ID="227535" DB="Orphanet" />
              <XRef ID="C0346153" DB="MedGen" />
              <XRef ID="MONDO:0016419" DB="MONDO" />
              <XRef Type="MIM" ID="114480" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3458383" SubmissionDate="2021-07-23" DateLastUpdated="2021-07-24" DateCreated="2021-07-24">
        <ClinVarSubmissionID localKey="SUB10063521" submittedAssembly="GRCh37" title="SUB10063521" />
        <ClinVarAccession Accession="SCV001760923" DateUpdated="2021-07-24" DateCreated="2021-07-24" Type="SCV" Version="1" SubmitterName="Laboratorio de Genética Hospitales Universitarios Virgen de las Nieves y Clínico San Cecilio (Granada, Spain), Hospitales Universitarios Virgen de las Nieves y Clínico San Cecilio (Granada, Spain)" OrgID="507275" OrganizationCategory="laboratory" OrgAbbreviation="Genetica" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-07-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>Null variant (frame-shift), in gene ATM for which loss-of-function is a known mechanism of disease (gene has 1 708 pathogenic LOF variants and gnomAD Loss-of-Function Observed/Expected = 0.603 is less than 0.763), associated with Breast cancer, susceptibility to and Ataxia-Telangiectasia. Variant not found in gnomAD exomes, Variant not found in gnomAD genomes. Pathogenic computational verdict based on 1 pathogenic prediction from phyloP vs no benign predictions. We have encountered this variant in 3 breast cancer patients and in 2 ovarian cancer. All of them belong to gypsy ethnicity and apparently unrelated families.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation Type="general">
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Gypsy</Ethnicity>
              <GeographicOrigin>Spain</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">35</Age>
              <Age Type="maximum" age_unit="years">70</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>mixed</Gender>
              <FamilyData NumFamiliesWithVariant="5" />
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="5" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="5" />
            </ObservedData>
            <Comment>We have encountered this variant in 3 breast cancer patients and in 2 ovarian cancer. All of them belong to gypsy ethnicity and apparently unrelated families.</Comment>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ATM">
              <Name>ATM serine/threonine kinase</Name>
            </Gene>
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000051.3:exon 63</GeneLocation>
          </Location>
          <FunctionalConsequence Value="Unknown function" />
          <AttributeSet>
            <Attribute Type="HGVS">NM_000051.3:c.9007_9034del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="114480" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10063521</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3751718" SubmissionDate="2021-09-14" DateLastUpdated="2021-09-24" DateCreated="2021-09-24">
        <ClinVarSubmissionID localKey="NM_000051.3:c.9007_9034del" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001911493" DateUpdated="2021-09-24" DateCreated="2021-09-24" Type="SCV" Version="1" SubmitterName="Spanish ATM Cancer Susceptibility Variant Interpretation Working Group" OrgID="508122" OrganizationCategory="consortium" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-06-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">30192042</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27664052</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11298136</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31050087</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33280026</ID>
          </Citation>
          <Comment>The c.9007_9034del (p.Asn3003Aspfs*6) variant deletes 28 bps in the last exon of ATM. It is predicted to create a frame shift but not to trigger nonsense-mediated mRNA decay (NMD). The truncation of the protein after residue 3003 deletes the FATC domain, critical for ATM activation as its interaction with the Tip60 histone acetyltransferase allows ATM acetylation and then autophosphorylation (PVS1_Strong, according to the PVS1 algorithm recommended by ACMG/AMP in 2018; PMID: 30192042). The variant is absent from the gnomAD v2.1.1 non-cancer dataset, in a position with adequate coverage (&gt;20x) (PM2; http://gnomad.broadinstitute.org). This variant has been reported in four homozygous ataxia-telangiectasia (AT) probands sharing a common haplotype, but also in two other unrelated homozygotes. It has been also detected in an AT proband in trans with the variant of unknown significance c. 9007A&gt;G, p.(Asn3003Asp). Together these allelic data award the c.9007_9034del variant with 1.25 points as per ClinGen SVI Recommendation for in trans Criterion (PM3; PMID: 27664052, 11298136, 31050087). Lymphoblastoid cell lines from independent homozygous carrier A-T patients showed trace or null amounts of ATM protein, no ATM autophosphorylation activity, reduced levels of phosphorylation of two substrates and intermediate radiosensitivity and high cell-cycle arrest in G2-M in response to a DNA damaging agent (PS3; PMID: 27664052, 11298136). Therefore, this variant meets criteria to be classified as pathogenic. Adapted ACMG/AMP rules applied as defined by the Spanish ATM working group: PVS1_Strong + PM2 + PM3 + PS3 (PMID: 33280026).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Feliubadaló L et al. (Clin Chem 2021)</Attribute>
          <Citation>
            <ID Source="PubMed">33280026</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>European caucasoid</Ethnicity>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
              <Indication Type="Indication">
                <Trait Type="Disease">
                  <Name>
                    <ElementValue Type="Preferred">Breast cancer, susceptibility to</ElementValue>
                  </Name>
                </Trait>
              </Indication>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
              <ObsMethodAttribute>
                <Attribute Type="TestingLaboratory">Molecular Diagnostics Laboratory, Hereditary Cancer Program, Catalan Institute of Oncology, Granvia de l’Hospitalet 199-203, 08908 L’Hospitalet de Llobregat, Barcelona, Spain</Attribute>
              </ObsMethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SampleLocalID">I-00196</Attribute>
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">Bilateral breast cancer</ElementValue>
                </Name>
              </Trait>
            </TraitSet>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>European caucasoid</Ethnicity>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
              <Indication Type="Indication">
                <Trait Type="Disease">
                  <Name>
                    <ElementValue Type="Preferred">Breast cancer, susceptibility to</ElementValue>
                  </Name>
                </Trait>
              </Indication>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
              <ObsMethodAttribute>
                <Attribute Type="TestingLaboratory">Molecular Diagnostics Laboratory, Hereditary Cancer Program, Catalan Institute of Oncology, Granvia de l’Hospitalet 199-203, 08908 L’Hospitalet de Llobregat, Barcelona, Spain</Attribute>
              </ObsMethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SampleLocalID">I-00197</Attribute>
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">Bilateral breast cancer</ElementValue>
                </Name>
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ATM" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000051.3:c.9007_9034del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10353687</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7061942" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2023-02-13">
        <ClinVarSubmissionID localKey="9265564|MedGen:C0004135" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003780633" DateUpdated="2024-02-20" DateCreated="2023-02-13" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-10-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">11298136</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17600866</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27664052</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31050087</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31050087</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Asn3003Aspfs*6) in the ATM gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 54 amino acid(s) of the ATM protein. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individuals with ataxia telangiectasia (PMID: 11298136, 17600866, 27664052, 31050087). It has also been observed to segregate with disease in related individuals. This variant is also known as 9008del28. ClinVar contains an entry for this variant (Variation ID: 1184270). Studies have shown that this premature translational stop signal alters ATM gene expression (PMID: 31050087). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ATM" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000011.9:g.108236071_108236098del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0004135" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9141938" SubmissionDate="2024-04-22" DateLastUpdated="2024-05-01" DateCreated="2024-05-01">
        <ClinVarSubmissionID localKey="100920964|OMIM:114480" />
        <ClinVarAccession Accession="SCV004932643" DateUpdated="2024-05-01" DateCreated="2024-05-01" Type="SCV" Version="1" SubmitterName="Myriad Genetics, Inc." OrgID="507240" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Myriad Autosomal Dominant, Autosomal Recessive and X-Linked Classification Criteria (2023)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/8ufcwsf2/myriad_genetics_classification_criteria_2023.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ATM" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="hg19" Chr="11" alternateAllele="C" referenceAllele="CAACAAAGTAGCTGAACGTGTCTTAATGA" start="108236070" stop="108236098" />
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">100920964</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="114480" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14395420</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3458383" TraitType="Disease" MappingType="XRef" MappingValue="114480" MappingRef="OMIM">
        <MedGen CUI="C0346153" Name="Familial cancer of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3751718" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3751718" TraitType="Finding" MappingType="Name" MappingValue="Bilateral breast cancer" MappingRef="Preferred">
        <MedGen CUI="CN235586" Name="bilateral breast cancer" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3751718" TraitType="Finding" MappingType="Name" MappingValue="Bilateral breast cancer" MappingRef="Preferred">
        <MedGen CUI="CN235586" Name="bilateral breast cancer" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9141938" TraitType="Disease" MappingType="XRef" MappingValue="114480" MappingRef="OMIM">
        <MedGen CUI="C0346153" Name="Familial cancer of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7061942" TraitType="Disease" MappingType="XRef" MappingValue="C0004135" MappingRef="MedGen">
        <MedGen CUI="C0004135" Name="Ataxia-telangiectasia syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

